Evidence map›Paper›PMID 40444158›Full record

ArticleResearch in pharmaceutical sciences2025

Designing of a novel chimeric antimicrobial peptide against

Yasin Rakhshani, Jafar Amani, Hamideh Mahmoodzadeh Hosseini, Seyed Ali Mirhosseini, Fattah Sotoodeh Nejad Nematalahi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Research in pharmaceutical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yasin RakhshaniFaculty of Converging Sciences and Technologies, Science and Research Branch, Islamic Azad University, Tehran, I.R. Iran.
Jafar AmaniApplied Microbiology Research Center, Biomedicine Technologies Institute, Baqiyatallah University of Medical Sciences, Tehran, I.R. Iran.
Hamideh Mahmoodzadeh HosseiniApplied Microbiology Research Center, Biomedicine Technologies Institute, Baqiyatallah University of Medical Sciences, Tehran, I.R. Iran.
Seyed Ali MirhosseiniApplied Microbiology Research Center, Biomedicine Technologies Institute, Baqiyatallah University of Medical Sciences, Tehran, I.R. Iran.
Fattah Sotoodeh Nejad NematalahiFaculty of Converging Sciences and Technologies, Science and Research Branch, Islamic Azad University, Tehran, I.R. Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and purpose: The study aimed to design new chimeric antimicrobial peptides targeting Experimental approach: To design new chimeric peptides targeting Findings/Results: The M-CIT peptide was selected for synthesis in the first method, but it did not show significant activity against the target bacteria (MIC = 187.5 μM and MBC = 375 μM). In the second method, no suitable score was observed. However, the M-PEX12 peptide was synthesized in the second method, demonstrating antimicrobial activity against Conclusion and implications: Three methods were evaluated for designing new chimeric peptides, and the third method, which involved modifying the number of amino acids in the parental peptides while maintaining their similarity, was found to be the most suitable.

Indexed as

Acinetobacter baumanniAntimicrobial peptideDrug designHybrid peptidesModel membraneWeb servers

Identifiers

PMID40444158
PMCPMC12118782

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.